References
- Ministerio de Sanidad, Servicos Sociales, e Igualdad. Informe Nacional Sobre Los Progresos Realizados En La Aplicación Del Ungass España: Enero de 2013 – Diciembre de 2013. http://www.unaids.org/sites/default/files/country/documents//ESP_narrative_report_2014.pdf. Last updated March 31, 2014. Accessed October 30, 2015.
- Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: A randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461–471.10.7326/M14-1084
- Ribaudo H, Wang H, Na L. A phase III comparative study of three non-nucleoside reverse transcriptase inhibitor (NNRTI)-sparing antiretroviral regimens for treatment-naïve HIV-1 infected volunteers (The ARDENT Study). A5257 Core Primary Analysis Report. Data on file. September 24, 2013.
- Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Presented at: ISPOR 21st Annual International Meeting; May 2016; Washington DC.
- INEbase. Indice de Precios de Consumo, Base 2011. http://www.ine.es/dynt3/inebase/en/index.htm?padre=1936&capsel=1940. Accessed September 21, 2015.
- Consejo General de Colegios Oficiales de Farmacéuticos. BotPlus Web. https://botplusweb.portalfarma.com/. Accessed June 15, 2015.
- Llibre-Codina JM, Casado-Gomez MA, Sanchez-de la Rosa R, et al. Costes de la toxicidad asociada a los análogos de nucleósidos inhibidores de la transcriptasa inversa en pacientes con infección por el VIH-1. Enferm Infecc Microbiol Clin. 2007;25(2):98–107.10.1157/13098570
- Spanish Healthcare Costs Database e-Salud. Oblikue Consulting. http://www.oblikue.com/bddcostes/. Accessed May 2015.
- Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res. 2009;9(55).
- Lopez-Bastida J, Oliva J, Antonanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–520.10.1007/s10198-010-0244-4
- Berenguer J, Rivero A, Blasco AJ, et al. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS national plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2015;34(6):361–371.